We hypothesized that TGFβ1 was correlated with poor prognosis, might act as an indicator for tumor immune microenvironment of CC, and potential immune therapies targeting TGFβ1 might provide new hope to colon patients. This evidence concerns the gene TGFB1 and neoplasm.